A recent review found that most drugs for the management of obesity do not improve heart health or quality of life.

GLP-1 RA use more than doubled between 2017 and 2022, indicating significant increases among people with and without diabetes.

Elevated genetic risk for pulse pressure is linked to a higher likelihood of dementia-related mortality among older adults.

Blood-based biomarkers can help improve accuracy when diagnosing Alzheimer disease and related cognitive impairment or dementia.

The Food and Drug Administration (FDA) has granted Fast Track designation to remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer disease psychosis (ADP).

Consumers are being warned by the CDC to avoid shredded iceberg lettuce from certain restaurants and providers in a handful of states.

There is an association between higher p-tau217 levels and increased risk for adverse cognitive outcomes among older adults.

Experts push for improving cancer prevention initiatives as cancer incidence burden is predicted to reach more than 34 million by 2050.

The FDA accepts Dyne’s BLA with Priority Review for zeleciment rostudirsen in exon 51 skipping DMD, setting a PDUFA target action date of January 21, 2027.

The FDA has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, for adult hypercholesterolemia and HeFH.

Use of GLP-1 RAs is associated with a higher risk for ischemic optic neuropathy compared with SGLT2is and DPP4is.

Recent wildfires contribute to a significant reduction in air quality across the Midwestern and Northeastern parts of Canada and the US.